SCHEMBL21112932

SCHEMBL21112932

COc1ccc(N2CCN(C(=O)[C@H]3O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]3OC(C)=O)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.51
▸ AKR1C3 P42330 1/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ GAA P10253 4/20 0.47
▸ HTT P42858 3/20 0.47
▸ MAPK1 P28482 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ GFER P55789 2/20 0.44
▸ KMT2A Q03164 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ CTSB P07858 1/20 0.42
▸ CTSS P25774 1/20 0.42
▸ CTSK P43235 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24145064 0.92 SMN1; SMN2 (0.47) ALDH1A1AKR1C3L3MBTL1SMN1; SMN2GAA
SCHEMBL20873248 0.89 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2GAAMAPTKMT2A
SCHEMBL20873341 0.88 AKR1C3 (0.44) ALDH1A1AKR1C3SMN1; SMN2GAAMAPT
SCHEMBL20873315 0.88 MEN1 (0.50) ALDH1A1AKR1C3L3MBTL1SMN1; SMN2HTT
SCHEMBL20873345 0.88 TFPI2 (0.47) ALDH1A1AKR1C3SMN1; SMN2HTTMAPT
SCHEMBL24145057 0.81 TP53 (0.43) ALDH1A1SMN1; SMN2GAAMAPK1MAPT
SCHEMBL21112883 0.81 ALDH1A1 (0.53) ALDH1A1AKR1C3SMN1; SMN2HTTMAPK1
SCHEMBL24145051 0.81 MEN1 (0.45) ALDH1A1AKR1C3SMN1; SMN2HTTMAPT
SCHEMBL24145052 0.80 TFPI2 (0.42) AKR1C3L3MBTL1SMN1; SMN2HTTMAPK1
SCHEMBL21112925 0.78 GAA (0.47) ALDH1A1AKR1C3SMN1; SMN2GAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 ALDH1A1 1514/4885AKR1C3 1463/4885L3MBTL1 4705/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 ALDH1A1 1514/4885AKR1C3 1463/4885L3MBTL1 4705/4885
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 ALDH1A1 1514/4885AKR1C3 1463/4885L3MBTL1 4705/4885
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 ALDH1A1 1514/4885AKR1C3 1463/4885L3MBTL1 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback